The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EGFR blockade leads to singular oncogene-addiction in ETV6-NTRK3 transformed human epithelial cells and hypersensitization to entrectinib.
 
Nagarajan Kannan
No Relationships to Disclose
 
Guruprasad Kalthur
No Relationships to Disclose
 
Musheer Aalam
No Relationships to Disclose
 
Ishaq Viringipurampeer
No Relationships to Disclose
 
Chitra Priya Emperumal
No Relationships to Disclose
 
Philip A Beer
No Relationships to Disclose
 
Anguraj Sadanandam
Consulting or Advisory Role - Ploughshare Innovations
Research Funding - Bristol-Myers Squibb; Merck KGaA; Pierre Fabre
Patents, Royalties, Other Intellectual Property - • Prognostic and treatment response prediction in gastric cancer – Priority Patent CSC/BP7295892; Patent - ‘Colorectal cancer classification with differential prognosis and personalized therapeutic responses’ (patent number PCT/IB2013/060416).; Patent - “Molecular predictors of therapeutic response to specific anti-cancer agents” (patent number US9506926B2).; Patent - Patient classification and prognostic method (GEP-NET) – Priority Patent - EP18425009.0
 
Joaquin J. Garcia
No Relationships to Disclose
 
Jeffrey R. Janus
No Relationships to Disclose